Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Aitor Lanas-Gimeno, Gonzalo Hijos & Ángel Lanas. (2019) Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 18:11, pages 1043-1053.
Read now
Read now
G.-L. Cui, U. Syversen, C.-M. Zhao, D. Chen, H. L. Waldum. (2001) Long-term Omeprazole Treatment Suppresses Body Weight Gain and Bone Mineralization in Young Male Rats. Scandinavian Journal of Gastroenterology 36:10, pages 1011-1015.
Read now
Read now
Articles from other publishers (27)
Forough Saki, Mesbah Shams, Sanaz Dastghaib & Farhad Koohpeyma. (2023) Pantoprazole-Induced Bone Loss through Gastrin Secretion: A Stereological Study. BioMed Research International 2023, pages 1-11.
Crossref
Crossref
Donal Fitzpatrick, Rosaleen Lannon, Eamon Laird, Mary Ward, Leane Hoey, Catherine F. Hughes, J. J. Strain, Conal Cunningham, Helene McNulty, Anne M. Molloy & Kevin McCarroll. (2023) The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture—results of a large observational cohort study. Osteoporosis International.
Crossref
Crossref
Md. Saddam Hussain & Tanoy Mazumder. (2022) Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength. Journal of Basic and Clinical Physiology and Pharmacology 33:5, pages 567-579.
Crossref
Crossref
Iskandar Tamimi, Pablo Carnero, David Bautista, David Gonzalez, Pablo Rodrigo, María Jose. Bravo, Abel Gómez, Faleh Tamimi & David Garcia de Quevedo. (2022) Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty. Geriatric Orthopaedic Surgery & Rehabilitation 13, pages 215145932210916.
Crossref
Crossref
Silvia Irina Briganti, Anda Mihaela Naciu, Gaia Tabacco, Roberto Cesareo, Nicola Napoli, Pierpaolo Trimboli, Marco Castellana, Silvia Manfrini & Andrea Palermo. (2021) Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature. International Journal of Endocrinology 2021, pages 1-15.
Crossref
Crossref
Joo-Hyun Park, Jessie Lee, Su-Yeon Yu, Jin-Hyung Jung, Kyungdo Han, Do-Hoon Kim & Jinnie Rhee. (2020) Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatrics 20:1.
Crossref
Crossref
Joe D. Pagan, Laura Petroski-Rose, Alana Mann & Ashlee Hauss. (2020) Omeprazole Reduces Calcium Digestibility in Thoroughbred Horses. Journal of Equine Veterinary Science 86, pages 102851.
Crossref
Crossref
Benjamin Ka Seng Thong, Soelaiman Ima-Nirwana & Kok-Yong Chin. (2019) Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. International Journal of Environmental Research and Public Health 16:9, pages 1571.
Crossref
Crossref
Karen E. Hansen, Jeri W. Nieves, Sai Nudurupati, David C. Metz & Maria Claudia Perez. (2019) Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women. Gastroenterology 156:4, pages 926-934.e6.
Crossref
Crossref
Chandan Vangala, Jingbo Niu, Colin R. Lenihan, William E. Mitch, Sankar D. Navaneethan & Wolfgang C. Winkelmayer. (2018) Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology 13:10, pages 1534-1541.
Crossref
Crossref
Michael F. Vaezi, Yu-Xiao Yang & Colin W. Howden. (2017) Complications of Proton Pump Inhibitor Therapy. Gastroenterology 153:1, pages 35-48.
Crossref
Crossref
Colin R. Lenihan, Sumi Sukumaran Nair, Chandan Vangala, Venkat Ramanathan, Maria E. Montez-Rath & Wolfgang C. Winkelmayer. (2017) Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients. American Journal of Kidney Diseases 69:5, pages 595-601.
Crossref
Crossref
Federica Cavalcoli, Alessandra Zilli, Dario Conte & Sara Massironi. (2017) Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: A review. World Journal of Gastroenterology 23:4, pages 563.
Crossref
Crossref
Milena Saqui-Salces, Amy C. Tsao, Merritt G. GillillandIIIIII & Juanita L. Merchant. (2017) Weight gain in mice on a high caloric diet and chronically treated with omeprazole depends on sex and genetic background. American Journal of Physiology-Gastrointestinal and Liver Physiology 312:1, pages G15-G23.
Crossref
Crossref
Thevaraajan Jayaraman, Muhammad Ilham Abdul Hafidz, Nazri Mustaffa & Yeong Yeh Lee. (2016) Should I Be Concerned with the Long-Term Use of Proton Pump Inhibitor Therapy?. EMJ Gastroenterology, pages 74-81.
Crossref
Crossref
Andrew M. Hinson, Bekka M. Wilkerson, Ivy Rothman-Fitts, Ann T. Riggs, Brendan C. StackJr.Jr. & Donald L. Bodenner. (2015) Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults. Journal of the American Geriatrics Society 63:10, pages 2070-2073.
Crossref
Crossref
Yunju Jo, Eunkyoung Park, Sang Bong Ahn, Young Kwan Jo, Byungkwan Son, Seong Hwan Kim, Young Sook Park & Hyo Jeong Kim. (2015) A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut and Liver 9:5.
Crossref
Crossref
József Maléth & Péter Hegyi. (2013) Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?. Orvosi Hetilap 154:26, pages 1005-1009.
Crossref
Crossref
Yu-Xiao Yang. (2012) Chronic Proton Pump Inihibitor Therapy and Calcium Metabolism. Current Gastroenterology Reports 14:6, pages 473-479.
Crossref
Crossref
Laura E Targownik, William D Leslie, Shawn K Davison, David Goltzman, Sophie A Jamal, Nancy Kreiger, Robert G Josse, Stephanie M Kaiser, Christopher S Kovacs, Jerilynn C Prior & Wei Zhou. (2012) The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos). American Journal of Gastroenterology 107:9, pages 1361-1369.
Crossref
Crossref
Giovanni Gori, Giacomo Spinelli, Claudio Spinelli, Marco Tuccori, Corrado Blandizzi & Mario Del Tacca. (2010) Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia. Nature Reviews Gastroenterology & Hepatology 7:11, pages 642-646.
Crossref
Crossref
Yu–Xiao Yang & David C. Metz. (2010) Safety of Proton Pump Inhibitor Exposure. Gastroenterology 139:4, pages 1115-1127.
Crossref
Crossref
Nathan A. Merriman, Mary E. Putt, David C. Metz & Yu–Xiao Yang. (2010) Hip Fracture Risk in Patients With a Diagnosis of Pernicious Anemia. Gastroenterology 138:4, pages 1330-1337.
Crossref
Crossref
Laura E. Targownik, Lisa M. Lix, Stella Leung & William D. Leslie. (2010) Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology 138:3, pages 896-904.
Crossref
Crossref
Kit Ching Lai, Christopher H.K. Cheng & Po Sing Leung. (2007) The Ghrelin System in Acinar Cells. Pancreas 35:3, pages e1-e8.
Crossref
Crossref
Maarten W. Taal, Tahir Masud, Desmond Green & Michael J. D. Cassidy. (1999) Risk factors for reduced bone density in haemodialysis patients. Nephrology Dialysis Transplantation 14:8, pages 1922-1928.
Crossref
Crossref
Rebecca Gagnemo-Persson, Per Persson, Tomas Bryngelsson, Britt Greén & Rolf Håkanson. (1999) Rat stomach ECL-cell histidine decarboxylase activity is suppressed by ergocalciferol but unaffected by parathyroid hormone and calcitonin. Regulatory Peptides 79:2-3, pages 131-139.
Crossref
Crossref